Nichi-Iko Pharmaceutical Co., Ltd

Nichi-Iko Pharmaceutical Co. in its US$ 100 million sale to Ellimist Singapore Pte. Ltd.


Nichi-Iko Pharmaceutical Co., Ltd


$100 million


Mergers and Acquisitions

Date Closed

February 2023


Pharmaceuticals and Life Sciences

Lead Office



On February 28, 2023, Nichi-Iko Pharmaceutical Co., Ltd. sold all issued and outstanding shares of its wholly owned subsidiaries, Sagent Pharmaceuticals, based in Wyoming, and Omega Laboratories Ltd., based in Montreal, to Ellimist Singapore Pte. Ltd. for an aggregate purchase price of US$100 million.

Nichi-Iko Pharmaceutical Co.,Ltd. is a Japanese company that focuses on manufacturing and selling pharmaceutical and medical products.

Osler, Hoskin & Harcourt LLP advised Nichi-Iko Pharmaceutical Co. with a team led by Vincent de Grandpré (IP) and Hugo-Pierre Gagnon (Corporate) and consisting of Josh Blatt (Corporate), Alain Fournier and Jean-Philippe Dionne (Tax), Julien Ranger-Musiol and Jeremy Perron (Pension, Benefits & Employment), Shuli Rodal (Competition), Susan Newell (Health), Jennifer Fairfax (Environmental), Yan Besner and Natasha Vincelli (Real Estate), Alan Kenigsberg and Malcolm Aboud (Sanctions and Anti-Corruption) and Joanna Fine, Adam LaRoche and Gemma Devir (Privacy).